Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
Toediening AAV5-hFVIII-SQ geassocieerd met normalisatie factor VIII-activiteit
jan 2018 | Benigne hematologie